Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?

Lancet Oncol. 2013 Oct;14(11):e438. doi: 10.1016/S1470-2045(13)70412-1.

Authors

Yulong Zheng¹, Nong Xu¹, Jianying Zhou²

Affiliations

¹ Department of Medical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China.
² Department of Respiratory Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China. Electronic address: drzjy@163.com.

PMID: 24079869
DOI: 10.1016/S1470-2045(13)70412-1

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Female
Humans
Lung Neoplasms / drug therapy*
Male